Veru Inc

NASDAQ:VERU   3:59:55 PM EDT
8.60
-0.23 (-2.60%)
Products

Veru Announces Positive Phase 2 Clinical Data Efficacy Of Enobosarm Therapy Correlates With Androgen Receptor Levels In Ar+Er+Her2- Metastatic Breast Cancer Presented At The 2021 Asco Annual Mee

Published: 06/07/2021 13:14 GMT
Veru Inc (VERU) - Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates With Androgen Receptor Levels in Ar+er+her2- Metastatic Breast Cancer Presented at the 2021 Asco Annual Meeting.
Veru Inc - in Phase 2 Study, Enobosarm Had Most Significant Antitumor Effects in Heavily Pretreated Ar+er+ Metastatic Breast Cancer Subjects.
Veru Inc - Advancing Enobosarm Into a Phase 2 Clinical Study, in 2nd Line Metastatic Setting.
Veru Inc - Expect Phase 2 to Commence in Calendar Q3 2021.